流行の初期に診断された米国人の癌患者の1年間の死亡率に対するCOVID-19の最小限の影響
PubMedで要約を見る
まとめ
この要約は機械生成です。COVID-19 パンデミックで診断されたがん患者はリスクに直面しましたが,がんは依然として主要な死因でした. COVID-19は,ほとんどのがんの全体的な死亡率に大きな影響を与えない.
科学分野
- 腫瘍学
- 流行病学について
- 公衆衛生
背景
- 癌の患者,特に免疫抑制の患者さんは,COVID-19のパンデミックの間,より脆弱だったかもしれません.
- パンデミック中の癌患者の死亡原因を評価することは,病気の影響を理解し,医療戦略を伝えるために極めて重要です.
研究 の 目的
- 2018年と比較して2020年に診断された癌患者の死亡原因 (がん,COVID-19,その他) を評価する.
- 1年間の特定原因による死亡率を,がんのタイプ,ステージ,および診断時の年齢によって分析する.
- COVID-19が死亡原因に及ぼす影響を対事実分析で推定する.
主な方法
- 2020年 (N=503,128) と2018年 (N=537,006) に診断されたがん患者のサーベイランス,疫学,および最終結果 (SEER) -22のデータを使用した.
- 1年間の特定原因による死亡率に焦点を当て,がん,COVID-19,その他の原因による死亡を調査した.
- 死亡原因としてCOVID-19が排除された場合の死亡率の割合を評価するために対事実分析を実施した.
主要な成果
- 2020年,がんは死亡の主な原因 (15.8%),次に他の原因 (3.3%) とCOVID-19 (0.7%) でした.
- COVID-19は,がん患者の死亡率のわずかな割合を占め,1.2% (臓がん) から9% (前立腺がん) までであった.
- 対照的な分析は,COVID-19が肺癌および臓癌を除いて,競合する原因による死亡率に限られた影響を及ぼしたことを示した.
結論
- 2020年に診断されたがん患者の主な死因はがんでした.
- COVID-19は,ほとんどのがんの死亡率の全体的な状況に実質的な変化をもたらさなかった.
- 発見は将来の健康危機における癌患者の過剰死亡率を最小限に抑えるための医療戦略を導くことができます.
関連する概念動画
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

